pantoprazole has been researched along with Stomach Neoplasms in 26 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Stomach Neoplasms: Tumors or cancer of the STOMACH.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The present study was conducted to explore the effect of pantoprazole on gastric adenocarcinoma through the regulation of Wnt/β-catenin signaling." | 7.79 | Effect of pantoprazole on human gastric adenocarcinoma SGC7901 cells through regulation of phospho‑LRP6 expression in Wnt/β-catenin signaling. ( Chen, M; Guo, H; Huang, S; Liu, P; Shen, W; Shen, Y; Zhang, L; Zou, X, 2013) |
| "To investigate reversal effects of pantoprazole (PPZ) on multidrug resistance (MDR) in human gastric adenocarcinoma cells in vivo and in vitro." | 7.78 | Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling pathway in vitro and in vivo. ( Chen, M; Huang, SL; Yang, VW; Zhang, B; Zhang, XQ; Zhu, H; Zou, XP, 2012) |
| " The present study was conducted to explore the effect of pantoprazole on gastric adenocarcinoma through the regulation of Wnt/β-catenin signaling." | 3.79 | Effect of pantoprazole on human gastric adenocarcinoma SGC7901 cells through regulation of phospho‑LRP6 expression in Wnt/β-catenin signaling. ( Chen, M; Guo, H; Huang, S; Liu, P; Shen, W; Shen, Y; Zhang, L; Zou, X, 2013) |
| "To investigate reversal effects of pantoprazole (PPZ) on multidrug resistance (MDR) in human gastric adenocarcinoma cells in vivo and in vitro." | 3.78 | Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling pathway in vitro and in vivo. ( Chen, M; Huang, SL; Yang, VW; Zhang, B; Zhang, XQ; Zhu, H; Zou, XP, 2012) |
| " We aimed to prospectively compare the effects of continuous infusion and intermittent dosing with pantoprazole on preventing gastric ESD-related bleeding." | 2.90 | Continuous Infusion versus Intermittent Dosing with Pantoprazole for Gastric Endoscopic Submucosal Dissection. ( Baek, DH; Jeon, HK; Kim, DU; Kim, GH; Lee, BE; Seo, JH; Song, GA, 2019) |
| " However, effective dosing or scheduling of proton pump inhibitors for the prevention of delayed bleeding after endoscopic resection remains unclear." | 2.84 | Standard and double-dose intravenous proton pump inhibitor injections for prevention of bleeding after endoscopic resection. ( Choe, JW; Hyun, JJ; Jung, SW; Jung, YK; Kim, SY; Koo, JS; Lee, SW; Yim, HJ, 2017) |
| " Several studies have linked the long-term use of PPIs to a potentially increased risk of gastric cancer." | 1.72 | Suppression of vacuolar-type ATPase and induction of endoplasmic reticulum stress by proton pump inhibitors. ( Lee, WP, 2022) |
| "However, whether PPIs suppress gastric cancer by targeting TERT remains elusive." | 1.51 | Proton pump inhibitor pantoprazole inhibits gastric cancer metastasis via suppression of telomerase reverse transcriptase gene expression. ( Cao, Y; Kang, W; Ling, T; Qian, L; Wang, L; Xu, G; Zhang, B; Zhang, W; Zhao, D; Zhaxi, P; Zou, X, 2019) |
| "We compared the viability of gastric cancer cells and epithelia cells in buffered and unbuffered culture conditions with PPZ treatment by WST-8 assay." | 1.39 | Proton pump inhibitor selectively suppresses proliferation and restores the chemosensitivity of gastric cancer cells by inhibiting STAT3 signaling pathway. ( Chen, M; Ding, X; Huang, S; Zhang, X; Zou, X, 2013) |
| "This is the first report of a gastric Burkitt's lymphoma responding to H pylori eradication." | 1.35 | Complete remission of gastric Burkitt's lymphoma after eradication of Helicobacter pylori. ( Baia, M; Baumgaertner, I; Charachon, A; Copie-Bergman, C; Delchier, JC; Haioun, C; Levy, M; Sobhani, I, 2009) |
| "Treatment of human gastric cancer cells with proton pump inhibitors significantly attenuated cell viability in a time- and dose-dependent manner." | 1.35 | Blockage of intracellular proton extrusion with proton extrusions with proton pump inhibitor induces apoptosis in gastric cancer. ( Cheong, JY; Cho, SW; Kim, DK; Lee, KJ; Park, HJ; Yeo, M, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (38.46) | 29.6817 |
| 2010's | 15 (57.69) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, WP | 1 |
| Souto Filho, JTD | 1 |
| Lemos, LVB | 1 |
| Vieira Junior, MC | 1 |
| Barboza, KP | 1 |
| Castelar, BM | 1 |
| Ribeiro, AEL | 1 |
| da Silva, FC | 1 |
| Lee, BE | 1 |
| Kim, GH | 1 |
| Song, GA | 1 |
| Seo, JH | 1 |
| Jeon, HK | 1 |
| Baek, DH | 1 |
| Kim, DU | 1 |
| Zhang, B | 3 |
| Ling, T | 2 |
| Zhaxi, P | 1 |
| Cao, Y | 1 |
| Qian, L | 1 |
| Zhao, D | 1 |
| Kang, W | 1 |
| Zhang, W | 1 |
| Wang, L | 2 |
| Xu, G | 2 |
| Zou, X | 5 |
| Shen, W | 2 |
| Chen, M | 5 |
| Shen, Y | 2 |
| Huang, S | 4 |
| Guo, H | 1 |
| Zhang, L | 2 |
| Liu, P | 1 |
| Ding, X | 1 |
| Zhang, X | 2 |
| Baeg, MK | 1 |
| Choi, MG | 2 |
| Moon, SJ | 1 |
| Lim, CH | 1 |
| Kim, JS | 1 |
| Cho, YK | 2 |
| Park, JM | 2 |
| Lee, IS | 2 |
| Kim, SW | 2 |
| Choi, KY | 2 |
| Yang, Y | 1 |
| Shi, X | 1 |
| Liao, W | 1 |
| Cheng, AS | 1 |
| Yan, H | 1 |
| Fang, C | 1 |
| Zhang, S | 1 |
| Shen, S | 1 |
| Chen, G | 1 |
| Lv, Y | 1 |
| Zhuge, Y | 1 |
| Schneider, JL | 1 |
| Kolitsopoulos, F | 1 |
| Corley, DA | 1 |
| Jung, YS | 1 |
| Kim, KO | 1 |
| Lee, SH | 2 |
| Jang, BI | 1 |
| Kim, TN | 1 |
| Jung, SW | 1 |
| Kim, SY | 1 |
| Choe, JW | 1 |
| Hyun, JJ | 1 |
| Jung, YK | 1 |
| Koo, JS | 1 |
| Yim, HJ | 1 |
| Lee, SW | 1 |
| Feng, S | 1 |
| Zheng, Z | 1 |
| Feng, L | 1 |
| Yang, L | 1 |
| Chen, Z | 1 |
| Lin, Y | 1 |
| Gao, Y | 1 |
| Chen, Y | 1 |
| Oh, TH | 1 |
| Jung, HY | 1 |
| Choi, KD | 1 |
| Lee, GH | 2 |
| Song, HJ | 1 |
| Choi, KS | 1 |
| Chung, JW | 1 |
| Byeon, JS | 1 |
| Myung, SJ | 1 |
| Yang, SK | 1 |
| Kim, JH | 1 |
| Baumgaertner, I | 1 |
| Copie-Bergman, C | 1 |
| Levy, M | 1 |
| Haioun, C | 1 |
| Charachon, A | 1 |
| Baia, M | 1 |
| Sobhani, I | 1 |
| Delchier, JC | 1 |
| Kim, JY | 1 |
| Kim, N | 1 |
| Park, HK | 1 |
| Jo, HJ | 1 |
| Shin, CM | 1 |
| Park, YS | 1 |
| Hwang, JH | 1 |
| Kim, JW | 1 |
| Jeong, SH | 1 |
| Lee, DH | 1 |
| Nam, RH | 1 |
| Kim, JM | 1 |
| Lee, JH | 1 |
| Jung, HC | 1 |
| Song, IS | 1 |
| Wu, Y | 1 |
| Kım, KJ | 1 |
| Park, MI | 1 |
| Park, SJ | 1 |
| Cho, SW | 3 |
| Moon, W | 1 |
| Kim, GM | 1 |
| Kim, WM | 1 |
| Huang, SL | 1 |
| Zhang, XQ | 1 |
| Zhu, H | 1 |
| Yang, VW | 1 |
| Zou, XP | 1 |
| Hiramoto, JS | 1 |
| Terdiman, JP | 1 |
| Norton, JA | 1 |
| Yeo, M | 2 |
| Kim, DK | 2 |
| Kim, YB | 1 |
| Oh, TY | 1 |
| Lee, JE | 1 |
| Kim, HC | 1 |
| Hahm, KB | 1 |
| Wöhrer, S | 1 |
| Bartsch, R | 1 |
| Hejna, M | 1 |
| Drach, J | 1 |
| Raderer, M | 1 |
| Oh, JH | 1 |
| Dong, MS | 1 |
| Paik, CN | 1 |
| Jeong, JJ | 1 |
| Han, SW | 1 |
| Chung, IS | 1 |
| Jeong, HK | 1 |
| Park, CH | 1 |
| Jun, CH | 1 |
| Kim, HI | 1 |
| Kim, HS | 1 |
| Choi, SK | 1 |
| Rew, JS | 1 |
| Park, HJ | 1 |
| Cheong, JY | 1 |
| Lee, KJ | 1 |
3 reviews available for pantoprazole and Stomach Neoplasms
| Article | Year |
|---|---|
Long-term complete remission of primary gastric plasmacytoma following endoscopic resection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Gastric Mucosa; Gastroscopy; H | 2017 |
Evidence-based analysis: postoperative gastric bleeding: etiology and prevention.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cost-Benefit Analysis; D | 2003 |
[Eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2005 |
7 trials available for pantoprazole and Stomach Neoplasms
| Article | Year |
|---|---|
Continuous Infusion versus Intermittent Dosing with Pantoprazole for Gastric Endoscopic Submucosal Dissection.
Topics: Aged; Endoscopic Mucosal Resection; Female; Gastrointestinal Hemorrhage; Gastroscopy; Humans; Infusi | 2019 |
Preprocedural rabeprazole treatment before endoscopic submucosal dissection for gastric neoplasms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Dissection; Female; Gastric Mucosa; Gastrointestinal | 2014 |
[Comparison on Oral versus Intravenous Proton Pump Inhibitors for Prevention of Bleeding after Endoscopic Submucosal Dissection of Gastric Lesions].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Anticoagulants; Endoscopic Muco | 2016 |
Standard and double-dose intravenous proton pump inhibitor injections for prevention of bleeding after endoscopic resection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Aged; Dose-Response Relationship, Drug; Drug Admin | 2017 |
Effective administration method of intravenous proton pump inhibitor: a novel testing using a BRAVO catheterless pH monitoring system.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Analysis of Variance; Female; Gastric Acidity Determi | 2011 |
Low-dose intravenous pantoprazole for optimal inhibition of gastric acid in Korean patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylas | 2007 |
A prospective randomized trial of either famotidine or pantoprazole for the prevention of bleeding after endoscopic submucosal dissection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Dissection; Famotidine; Female; Ga | 2007 |
16 other studies available for pantoprazole and Stomach Neoplasms
| Article | Year |
|---|---|
Suppression of vacuolar-type ATPase and induction of endoplasmic reticulum stress by proton pump inhibitors.
Topics: Activating Transcription Factor 6; Dexlansoprazole; Endoplasmic Reticulum Stress; Esomeprazole; Huma | 2022 |
Proton pump inhibitor pantoprazole inhibits gastric cancer metastasis via suppression of telomerase reverse transcriptase gene expression.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Chromatin Assembly and Disassembly; | 2019 |
Effect of pantoprazole on human gastric adenocarcinoma SGC7901 cells through regulation of phospho‑LRP6 expression in Wnt/β-catenin signaling.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Apoptosis; Cell Line, Tumor; Cell Prolifera | 2013 |
Proton pump inhibitor selectively suppresses proliferation and restores the chemosensitivity of gastric cancer cells by inhibiting STAT3 signaling pathway.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tum | 2013 |
Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin signaling and epithelial-mesenchymal transition.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; | 2015 |
Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; California; Cohort Studies; Dose-R | 2016 |
Proton pump inhibitor pantoprazole inhibits the proliferation, self‑renewal and chemoresistance of gastric cancer stem cells via the EMT/β‑catenin pathways.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; | 2016 |
Degree of healing and healing-associated factors of endoscopic submucosal dissection-induced ulcers after pantoprazole therapy for 4 weeks.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Adenoma; Aged; Aged, 80 and over; Anti-Ulce | 2009 |
Complete remission of gastric Burkitt's lymphoma after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Burkitt Lymphoma; Female; Gastric | 2009 |
[Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Chronic Di | 2011 |
Effects of pantoprazole as a HIF-1α inhibitor on human gastric adenocarcinoma sgc-7901 cells.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Animals; Anti-Ulcer Agents; Apoptosis; Blot | 2012 |
Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling pathway in vitro and in vivo.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Animals; Antineoplastic Agents; ATP Binding | 2012 |
[Patient with increased stomach cancer risk. Helicobacter can cause damage here].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2002 |
Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Annexin A5; Anti-Ulcer Agents; Apoptosis; Benzimid | 2004 |
Routine application of the proton-pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti- | 2005 |
Blockage of intracellular proton extrusion with proton extrusions with proton pump inhibitor induces apoptosis in gastric cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Apoptosis; Caspases; Cell Line, Tumor; Culture Media; Enzym | 2008 |